Manufacturing AstraZeneca teams up with G42 Healthcare to increase drug...

AstraZeneca teams up with G42 Healthcare to increase drug production in Abu Dhabi

-

AstraZeneca has signed a strategic partnership agreement with G42 Healthcare to manufacture medicinal therapies in Abu Dhabi. The agreement concentrates on teamwork across four areas; research and development, global-scale sustainability, innovation, and localizing innovative industries. G42 is a healthcare firm that is powered by Artificial Intelligence while AstraZeneca is one of the top biopharma companies in the world.

This arrangement is in line with the “Make it in the Emirates” initiative which was launched to further UAE’s image as an attractive location for both global as well as local investors. The Ministry of Industry and Advanced Technology launched the initiative to make UAE a global hub for the industries of tomorrow.

The agreement signing took place in the presence of the Ministry of Industry and Advanced Technology and the Ministry of Health and Prevention. This partnership also contributes to UAE’s attempt to promote a knowledge-based economy in the country.

The industrial sector was provided incentives by the UAE that come in the form of top-of-the-line infrastructure, flexible financing solutions, an advanced transportation network, and a supportive legislative framework. All these incentives aim to generate investment opportunities, increase efficiency, make national partnerships with international investors stronger, and enhance product quality to make them globally competitive.

AstraZeneca’s Cluster President for GCC and Pakistan, Sameh ElFangary said, “AstraZeneca is honored to be a long-term, trusted partner of the UAE in bringing innovative healthcare locally, and we applaud Abu Dhabi’s ambition to become a regional life sciences hub. We are now taking our comprehensive existing partnership with G42 Healthcare to new heights, accelerating it across local manufacturing, research, innovation, and sustainability. I’m confident that this partnership will contribute greatly to advancing a sustainable health ecosystem that enables transforming patient outcomes.”

The collaboration also helps with Abu Dhabi’s Industrial Strategy of doubling the manufacturing sector size by 2031. It will inflate Abu Dhabi’s presence in life science R&D along with allowing innovation in all sectors of healthcare.

Department of Health – Abu Dhabi (DoH) looks to play its part in the country’s knowledge-based economy by creating unique jobs that require both human capital and a highly skilled workforce. This agreement will also aid in raising the industrial sector’s contribution to GDP and help increase non-oil exports.

In 2021, UAE increased its scientific and clinical research capabilities twofold as more research projects were welcomed compared to the previous half a decade.

Undersecretary of DoH, Dr. Jamal Mohammed Al Kaabi said that while DoH is partnering with significant pharma entities from around the world, the goal is to maintain the quick advancement of our revolutionary healthcare model driven by a hi-tech ecosystem.

The CEO of G42 Healthcare, Ashish Koshy expressed confidence in the potential that is held in continuing a partnership with AstraZeneca. He believes that it will promote innovation in the country’s local manufacturing and enable the country to discover bigger possibilities in the field of clinical research that will be beneficial for the patients in the country as well as around the world.

+ posts

Latest news

FDA and CDC exploring unlikely relation between COVID-19 vaccine and stroke

The FDA and CDC have brought out new revelations that the revised COVID-19 injection from Pfizer Inc...

Disappointing sales prompt AstraZeneca to pull out leukemia drug Lumoxiti from U.S. market

In a letter shared with healthcare providers, AstraZeneca has announced that it will be pulling its leukemia...

Sanofi’s Venture Capital units to receive over $750 million in investment to boost firm’s investment capabilities 

After a successful last year in which Sanofi Ventures made its second-highest number of deals, 10 rounds...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you